Urolog. pro Praxi, 2008; 9(2): 78-81

Cardiovascular parameters of erectile dysfunction

MUDr. Ta»ána ©rámková CSc1,2
1 Ústav lékařské psychologie LF MU Brno
2 Klinika traumatologie Úrazová nemocnice a LF MU, Brno

Erectile dysfunction is a common problem of middle-aged and elderly men. The etiology is organic in about 80 % and the most frequent cause is cardiovascular. Erectile dysfunction and coronary artery disease have the same morphological base and hence the same risk factors. Therefore, coronary artery disease appears in patients with erectile dysfunction and vice versa. Erectile dysfunction can be included in the risk factors of coronary artery disease. That is why we should search for coronary artery disease in patients who have been diagnosed with erectile dysfunction. We should also actively screen these patients and treat them effectively.

Keywords: erectile dysfunction, cardivasculat disease, coronary artery disease, PDE-5 inhibitors

Published: May 21, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©rámková T. Cardiovascular parameters of erectile dysfunction. Urol. praxi. 2008;9(2):78-81.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Breza J. Erektilné poruchy. Martin: Osveta, 1994: 270 s.
    2. Conti CR, Pepione CJ, Sweenwy M. Efficacy ad safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83: 29C-34C. Go to original source... Go to PubMed...
    3. De Busc R, Drory R, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of the Princeton consensus panel. Am J Cardiol 2000; 86: 175-181. Go to original source... Go to PubMed...
    4. Dean J, Eardley I, Brock G, Longworth J, Rubio-Aurioles E. Validation and psychometric properties of the English-language version of the female assessment of male erectile dysfunction detection scale (FAME). J Sex Med 2008; 5(Suppl 2): 91.
    5. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl. 2002; 4: H32-H47. Go to original source...
    6. Goldstein I, et al. Oral sildenafil for the treatment of erectile dysfunction. British Journal of Urology, 1997; 80(Suppl. 2): 901.
    7. Greenistein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease corelate with erectile function? Int J Impot Res 1997; 9: 123-126. Go to original source... Go to PubMed...
    8. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. The New England Journal of Medicine. 2000; 342, 22: 1622-1626. Go to original source... Go to PubMed...
    9. Jackson G, Kloner RA, Costigan TM, Warner MR, Emmick JT. Update on clinical trials of tadalafil demonstrates no increased risk of cardivascular adverse events. J Sex Med 2004; 1: 161-167. Go to original source... Go to PubMed...
    10. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile function a marker of cardiovascular disease? Int J Clin Pract 2001; 55: 614-618. Go to original source... Go to PubMed...
    11. Kratochvíl S. Léčení sexuálních dysfunkcí. Praha: Grada Publishing, 1999: 249 s.
    12. Kloner R, Padma-Nathan H. Erectile dysfunction in patients with coronary artery disease. Int J Impot Res. 2005; 17(3): 209-215. Go to original source... Go to PubMed...
    13. Linet IO, Neff LL. Intracavernous prostaglandin E1 in erectile dysfunction. Clin. Investig. 1994; 72: 139-149. Go to original source... Go to PubMed...
    14. Nieschlag E, Behre HM. Andrology. Berlin-Heilderberg: Springer-Verlag, 1997: 437 s. Go to original source...
    15. Meluzín J. Erektilní dysfunkce a srdce. In: Erektilní dysfunkce pod lupou. Ed. Pacík D. Plzeň: Adéla, 2005: 9-16.
    16. Muller JE, Mittleman MA, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity: Low absolute risk and prevention by regular physical exertion. JAMA 1996; 275: 1405-1409. Go to original source... Go to PubMed...
    17. Pondělíčková J. Manľelská sexualita. Praha: Avicenum, 1986: 207 s.
    18. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol, 1996; 155(3): 802-815. Go to original source... Go to PubMed...
    19. Pritzker MR. The penile stress test: a window to the heart of man? 72nd Scientific Session of the American Heart Association, November 7-10, 1999, Atlanta, Abstrakt 104561.
    20. Sesti C, Florio V, Johnson EG, Kloner RA. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res. 2006, July 20: doi: 10. 1038/sj. ijir. 3901497. Go to original source... Go to PubMed...
    21. Shakir SAW, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. Brit Med J. 2001; 322: 651-652. Go to original source... Go to PubMed...
    22. Solomon H, Man JV, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003; 91: 230-231. Go to original source... Go to PubMed...
    23. ©rámková T, Mechl M. Prostaglandin E 1 (Caverject) v terapii erektilní dysfunkce. Prakt. Lék. 1997, 77, 6: 296 - 301.
    24. Wagner G., Mulhall J.: Pathophysiology and diagnosis of male erectile dysfunction. BJU Int 2001; 88, Suppl. 3.: 3 - 10. Go to original source... Go to PubMed...
    25. Weiss P, Zvěřina J.: Sexuální chování v ČR - situace a trendy. Praha: Portál, 2001: 159 s.
    26. Zvěřina J. Lékařská sexuologie. Praha, 1994: 181 s.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.